Merck's Bacterial-Infection Drug Recarbrio Approved by FDA

Date : 07/17/2019 @ 12:45PM
Source : Dow Jones News
Stock : Merck and Co Inc (MRK)
Quote : 86.72  -0.19 (-0.22%) @ 1:00AM

Merck's Bacterial-Infection Drug Recarbrio Approved by FDA

Merck (NYSE:MRK)
Historical Stock Chart

2 Months : From Jun 2019 to Aug 2019

Click Here for more Merck Charts.

By Dave Sebastian


Merck & Co. Inc. (MRK) said Wednesday the U.S. Food and Drug Administration has approved its Recarbrio drug injection for urinary-tract and intra-abdominal bacterial infections.

The New Jersey pharmaceutical company said it anticipates to make Recarbrio available later this year.

The drug is a combination of imipenem and cilastatin--both antibacterial components--as well as relebactam, which protects imipenem from certain enzymes, Merck said.

Relebactam received the FDA's Qualified Infectious Disease Product designation for the treatment of complicated urinary tract and complicated intra-abdominal bacterial infections, and the FDA gave Recarbrio's drug application a priority-review designation, the company said.


Write to Dave Sebastian at


(END) Dow Jones Newswires

July 17, 2019 07:30 ET (11:30 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest MRK Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.